[Ebook] The top 3 delays that plague specialty prescribing — according to providers

There are many stakeholders and steps involved in getting a specialty drug “from pen to pill” - from the point at...

Read More

What’s next for specialty? Seven predictions for 2016

2015 is in the rearview mirror, and in many ways, it was a year like no other for the specialty pharmaceutical...

Read More

Biosimilars: meet 2016’s solution to the specialty drug cost conundrum

If you work in the pharma or biotech industry, you’ve probably heard the buzz about biosimilars. And, there’s a good...

Read More
Page 0 of 1